CN104758511A - External medicine for treating primary trigeminal neuralgia - Google Patents

Abstract

The invention relates to an external medicine for treating primary trigeminal neuralgia. The external medicine comprises the following crude medicines in parts by weight: 10 parts of centipede, 10 parts of rhizoma arisaematis, 5 parts of olibanum, 5 parts of myrrh, 10 parts of trogopterus dung, 10 parts of saposhnicovia divaricata and 10 parts of semen strychni. A preparation method of the external medicine comprises the following steps: weighing the crude medicines, uniformly mixing the crude medicines, grinding the crude medicines into fine powder, and mixing the fine powder and rice vinegar into paste to obtain the external medicine. Clinical practices prove that the external medicine can be used for treating primary trigeminal neuralgia safety and effectively.

Description

A kind of medicine for external use being used for the treatment of primary trigeminal neuralgia

Technical field

The present invention relates to a kind of medicine for external use being used for the treatment of primary trigeminal neuralgia.

Background technology

Primary trigeminal neuralgia is also known as " face pain ", it is a kind of prosopalgic typical types, occur in the violent neuropathic pain of facial nervi trigeminus areal area, there is the feature of recurrent exerbation, be the commonly encountered diseases of neurosurgery, Neurology Department, frequently-occurring disease, in 40 years old adult, is more common in middle-aged and elderly people, women is common, falls ill at R)L.To fall ill hurried, all standing, present lightning sample, burn sample, the sample that lancinates, intractable and insufferable severity pain, patient is many dare not wipe face, feed.Swallow saliva and also there is obstacle, to daily life and work, there is material impact, be called as " the first under heaven pain ".In modern medicine, think that trigeminal neuralgia is a kind of difficult and complicated illness, the various activities of daily life all can cause disease to send out.

In Chinese medical discrimination theory, think that its cause of disease is that three YANG meridians network is subject to pathogen and infects, clinical its cause of disease is divided into internal injury and diseases caused by exogenous pathogenic factor, common to cause for wind-fire two heresy.The head of human body is yang-energy joint, if failure of defensive QI to protect the body against pathogen will cause wind and cold or wind heat invades, causes damage to human body.Cold blocks brothers' three YANG meridians network and causes pain.Endogenous cause of ill is mainly because the emotional instability of patient self causes.In clinical treatment, mainly to regulate QI and blood, expulsion cold is basic.

Summary of the invention

The present invention aims to provide for a kind of medicine for external use for the treatment of primary trigeminal neuralgia, by selecting suitable medical material and proportioning thereof, reaches the object of safe and effective treatment primary trigeminal neuralgia.

In order to achieve the above object, the present invention is by the following technical solutions:

Be used for the treatment of a medicine for external use for primary trigeminal neuralgia, it is characterized in that, the medical material adopted and weight proportion thereof are: Scolopendra 10 parts, Rhizoma Arisaematis 10 parts, Olibanum 5 parts, Myrrha 5 parts, Oletum Trogopterori 10 parts, Radix Saposhnikoviae 10 parts, Semen Strychni 10 parts.

Adopt following preparation method:

Take above-mentioned medical material, be total to porphyrize powder after mix homogeneously, then reconcile into paste with rice vinegar, to obtain final product.

Below in conjunction with clinical laboratory data, beneficial effect of the present invention is described:

1, physical data

Inventor accepts 70 routine trigeminal neuralgia Diseases for medical treatment between in May, 2013 ~ in May, 2014, wherein, women 43 example, male 27 example, the age is between 18 ~ 60 years old; Mean age is (43.6 ± 5.5) year, and the course of disease is between 7 days ~ 10 years.According to the mode of random controls, patient is divided into test group and matched group, often organizes 35 routine patients, the sex of two groups of contrast patients, age, substantially clinical data and symptom there was no significant difference, there is comparability.

2, test method

2.1 Therapeutic Method

Matched group gives conventional western medicine treatment, oral carbamazepine (Shanghai Xinyi Pharmaceutical Co., Ltd's production), each 0.1g, 3 times/d.One course for the treatment of was 30 days.

Test group patient uses the present invention according to the obtained unguentum of embodiment 1, coordinates medical proof fabric to stick in ramus of mandible: stick WANGU acupoint, Dicang point, cave, ShiShimonoseki; Ramus maxillaris: stick WANGU acupoint, fragrant cave, 400 caves, cave, ShiShimonoseki; Ramus ophthalmicus: stick WANGU acupoint, yang white cave, temple.Within every three days, change once.Successive administration 30 days.

2.2 curative effect determinate standards: 1. fully recover: trigeminal neuralgia clinical symptoms disappears completely, and in half a year, there is not recurrence; 2. effective: patient pain's transference cure, but occur recurrence in half a year, and the frequency of recurrence be 50% before treatment and more than; 3. effective: patient pain disappears substantially, but recurrence frequency decreases 25% ~ 50% compared with before treatment; 4. invalid: the clinical symptoms such as patient pain do not disappear.

3, therapeutic outcome

After treatment, matched group recovery from illness 0 example, effective 20 examples, effective 8, invalid 7 examples, effective percentage 80%.Experimental group recovery from illness 17 example, effective 8 examples, effective 10, invalid 0 example, effective percentage 100%.Be showed no obvious adverse reaction in two groups of therapeutic processes to occur.

Detailed description of the invention

In order to understand better and implement the present invention, further illustrate the present invention below in conjunction with specific embodiment.

embodiment 1

Be used for the treatment of a medicine for external use for primary trigeminal neuralgia, the medical material adopted and weight proportion thereof are: Scolopendra 10 parts, Rhizoma Arisaematis 10 parts, Olibanum 5 parts, Myrrha 5 parts, Oletum Trogopterori 10 parts, Radix Saposhnikoviae 10 parts, Semen Strychni 10 parts.

Adopt following preparation method:

Take above-mentioned medical material, be total to porphyrize powder after mix homogeneously, then reconcile into paste with rice vinegar, to obtain final product.

Using method:

Medical proof fabric is coordinated to stick in ramus of mandible: to stick WANGU acupoint, Dicang point, cave, ShiShimonoseki; Ramus maxillaris: stick WANGU acupoint, fragrant cave, 400 caves, cave, ShiShimonoseki; Ramus ophthalmicus: stick WANGU acupoint, yang white cave, temple.Within every three days, change once.

Claims (2)

1. be used for the treatment of a medicine for external use for primary trigeminal neuralgia, it is characterized in that, the medical material adopted and weight proportion thereof are: Scolopendra 10 parts, Rhizoma Arisaematis 10 parts, Olibanum 5 parts, Myrrha 5 parts, Oletum Trogopterori 10 parts, Radix Saposhnikoviae 10 parts, Semen Strychni 10 parts.

2. according to the medicine for external use for the treatment of primary trigeminal neuralgia according to claim 1, it is characterized in that, adopt following preparation method:

Take above-mentioned medical material, be total to porphyrize powder after mix homogeneously, then reconcile into paste with rice vinegar, to obtain final product.